Patents by Inventor Christian Theodoor Gerardus Smits

Christian Theodoor Gerardus Smits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Leptospira with increased antigenic mass
    Patent number: 10046038
    Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 14, 2018
    Assignee: Intervet Inc.
    Inventors: Christian Theodoor Gerardus Smits, Edwin Kets, Henriette Adriaanse
  • Leptospira With Increased Antigenic Mass
    Publication number: 20150306199
    Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.
    Type: Application
    Filed: December 20, 2013
    Publication date: October 29, 2015
    Applicant: Intervet Inc.
    Inventors: Christian Theodoor Gerardus Smits, Edwin Kets, Henriette Adriaanse
  • LEPTOSPIRA WITH INCREASED ANTIGENIC MASS
    Publication number: 20140178433
    Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific fatty acid: linoleic acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.
    Type: Application
    Filed: December 16, 2013
    Publication date: June 26, 2014
    Inventors: Edwin Kets, Christian Theodoor Gerardus Smits, Henriette Adriaanse
  • Process for the production of the toxin ApxI employing a culture medium comprising calcium-borogluconate complex
    Patent number: 8586331
    Abstract: The present invention pertains to a method to produce RTX-toxin Apxl by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, to which medium a calcium salt is added to form calcium ions in the medium, wherein the culturing medium contains borogluconate to form a calcium borogluconate complex in the medium.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: November 19, 2013
    Assignee: Intervet International B.V.
    Inventors: Simen-Jan Slagman, Christian Theodoor Gerardus Smits, Bayram Bulut
  • Process for the production of the toxins APXI or APXIII in a liquid culture medium under supply of air enriched in carbon dioxide
    Patent number: 8445235
    Abstract: The current invention pertains to a method to produce RTX-toxins ApxI or ApxIII by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, characterized in that air is passed through the medium, wherein the air has a carbon dioxide content above normal atmospheric level to increase RTX-toxin production during the production phase of the RTX-toxins.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: May 21, 2013
    Assignee: Intervet International B.V.
    Inventors: Simen-Jan Slagman, Christian Theodoor Gerardus Smits
  • PROCESS FOR THE PRODUCTION OF THE ACTINOBACILLUS PLEUROPNEUMONIAE TOXINS APXI OR APCIII IN A LIQUID CULTURE MEDIUM UNDER SUPPLY OF AIR ENRICHED IN CARBON DIOXIDE
    Publication number: 20110229934
    Abstract: The current invention pertains to a method to produce RTX-toxins ApxI or ApxIII by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, characterised in that air is passed through the medium, wherein the air has a carbon dioxide content above normal atmospheric level to increase RTX-toxin production during the production phase of the RTX-toxins.
    Type: Application
    Filed: November 25, 2009
    Publication date: September 22, 2011
    Inventors: Simen-Jan Slagman, Christian Theodoor Gerardus Smits